Track topics on Twitter Track topics that are important to you
Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.
Original Article: Allergan’s experimental migraine drug hits trial targetsNEXT ARTICLE
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...